Plus Therapeutics (NASDAQ:CNSY) Lowered to “Strong Sell” Rating by Zacks Research

Zacks Research downgraded shares of Plus Therapeutics (NASDAQ:CNSY) from a hold rating to a strong sell rating in a report published on Monday,Zacks.com reports.

Plus Therapeutics Stock Down 100.0%

Plus Therapeutics Company Profile

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases.